The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers

Clinical Cancer Research

Volumn 6, Issue 11, 2000, Pages 4278-4286

  Gunningham, Sarah P ^a   Currie, Margaret J ^a   Han, Cheng ^a   Robinson, Bridget A ^a   Scott, Prudence A E ^a   Harris, Adrian L ^b   Fox, Stephen B ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLT4 LIGAND; LIGAND; MESSENGER RNA; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; ALTERNATIVE RNA SPLICING; ANGIOGENESIS; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; RECEPTOR BINDING; TUMOR CELL; VASCULAR ENDOTHELIUM;

ALTERNATIVE SPLICING; BREAST NEOPLASMS; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 0033730360     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Vascular permeability factor (VPF, VEGF) in tumor biology
2. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
3. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
4. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast
5. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer
6. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis
7. Quantitative analysis of vascular endothelial growth factor in primary breast cancer
8. Vascular endothelial growth factor (VEGF) in human breast cancer: Correlation with disease-free survival
9. Vascular endothelial growth factor is of high prognostic value in nodenegative breast carcinoma
10. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma
11. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer
12. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinase
13. Vascular endothelial growth factor-related protein: A ligand and specific activator of the tyrosine kinase receptor Flt4
14. Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C localise to chromosomes 11q13 and 4q34 respectively
15. Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts
16. Proteolytic processing regulates receptor specificity and activity of VEGF-C
17. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia
18. VEGF-C receptor-binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development
19. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice
20. Vascular endothelial growth factors VEGF-B and VEGF-C
21. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development
22. Vascular endothelial growth factor C induces angiogenesis in vivo
23. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia
24. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation
25. Differential hormonal regulation of vascular endothelial growth factors VEGF, VEGF-B, and VEGF-C messenger ribo nucleic acid levels in cultured human granulosa-luteal cells
26. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors
27. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer
28. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
29. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors
30. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis
31. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features
32. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer
33. Grading of invasive carcinoma of the breast
34. A reliable external control for ribonuclease protection assays
35. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: An immunohistochemical study
36. Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1
37. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer
38. Relationship of elevated tumour thymidine phosphorylase in node positive breast carcinomas to the effects of adjuvant CMF
39. The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium
40. Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysis
41. Tumor angiogenesis in node-negative breast carcinomas: Relationship with epidermal growth factor receptor, estrogen receptor, and survival
42. Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients
43. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells
44. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast
45. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer
46. Molecular mediators of tumor angiogenesis: Enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer
47. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I. An inventory in search of autocrine and paracrine loops
48. Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity
49. Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival
50. Regulation of angiogenesis via vascular endothelial growth factor receptors
51. VEGF and VEGF-C: Specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane
52. Interaction with the phosphotyrosine binding domain/phosphotyrosine interacting domain of SHC is required for the transforming activity of the FLT4/VEGFR3 receptor tyrosine kinase
53. Biochemical characterization of two isoforms of FLT4, a VEGF receptor-related tyrosine kinase
54. FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter
55. Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis
56. Differential expression of vascular endothelial growth factor mRNA versus protein isoform expression in human breast cancer and relationship to elF-4E